Publications by Dr Emma Haagensen - ePrints

Browsing publications by Dr Emma Haagensen.

Newcastle Authors	Title	Year
Jun Lim Dr Emma Haagensen Dr Edmund Ong Dr Paul Hubbard	Exploring pre-clinical medical students' perception of and participation in active learning: A mixed-methods transnational study.	2025
Professor Iain Keenan Emily Green Dr Emma Haagensen Dr Rebecca Hancock Kayleigh Scotcher et al.	Pandemic-Era Digital Education: Insights from an Undergraduate Medical Programme	2022
Dr Corey Chan Dr Emma Haagensen Dr Hayeit Tensaout Dr Kate Rennie Dr Zakareya Gamie et al.	Co‑localisation of intra‑nuclear membrane type‑1 matrix metalloproteinase and hypoxia inducible factor‑2α in osteosarcoma and prostate carcinoma cells	2021
Dr Emma Haagensen Dr Ma Brenda Pancho Dr Scott Walker Bhavani Veasuvalingam Judy Bien et al.	The Effects of Integrative Study Support on the Type and Complexity of Student Study Skills Techniques	2021
Dr Emma Haagensen	The High-Affinity Interaction between ORC and DNA that Is Required for Replication Licensing Is Inhibited by 2-Arylquinolin-4-Amines	2017
Zak Gamie Dr Emma Haagensen Ricardo da Conceicao Ribeiro Professor Kenneth Dalgarno Dr Anja Krippner-Heidenreich et al.	TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data	2017
Dr Emma Haagensen	Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing	2016
Dr Gary Beale Dr Emma Haagensen Huw Thomas Lan Wang Charlotte Revill et al.	Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer	2016
Dr Emma Haagensen Huw Thomas Dr Ross Maxwell Professor Herbie Newell	Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037	2016
Dr Emma Haagensen Huw Thomas Dr Ross Maxwell Professor Herbie Newell	Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent	2016
Dr Emma Haagensen	Unreplicated DNA remaining from unperturbed S phases passes through mitosis for resolution in daughter cells	2016
Dr Emma Haagensen Huw Thomas Ian Wilson Dr Suzannah Harnor Sara Payne et al.	The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [¹⁸F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice	2013
Dr Emma Haagensen Suzanne Kyle Dr Gary Beale Dr Ross Maxwell Professor Herbie Newell et al.	The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition	2012